Clinical Efficacy and Tolerability of Ezetimibe in Combination With Atorvastatin in Japanese Patients With Hypercholesterolemia-Ezetimibe Phase IV Randomized Controlled Trial in Patients With Hypercholesterolemia

Current Therapeutic Research - Clinical and Experimental

Volumn 73, Issue 1-2, 2012, Pages 16-40

  Teramoto, Tamio ^a   Sawada, Teruo ^b   Iwamoto, Kazuya ^c   Daida, Hiroyuki ^d  

^a TEIKYO UNIVERSITY   (Japan)

^b Merck Sharp Dohm Res Labs Japan   (Japan)

^c BAYER YAKUHIN LTD   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

Atorvastatin; Clinical trial; Ezetimibe; Hypercholesterolemia; LDL cholesterol; Rosuvastatin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BLURRED VISION; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG FATALITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL CARCINOID TUMOR; GASTROINTESTINAL TUMOR; HEAT INJURY; HUMAN; HYPERCHOLESTEROLEMIA; JAPANESE; LEUKOCYTE COUNT; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCLE SPASM; OPEN STUDY; PARALLEL DESIGN; PHASE 4 CLINICAL TRIAL; PNEUMONIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RHINOPHARYNGITIS; SIDE EFFECT; STOMATITIS; THORAX PAIN; THROMBOCYTE COUNT; THYROTROPIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84858637993     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2012.02.002     Document Type: Article

References (31)

1. Okamura T., Tanaka H., Miyamatsu N., et al. The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis 2007, 190:216-223.
2. Okamura T., Kadowaki T., Hayakawa T., et al. What cause of mortality can we predict by cholesterol screening in the Japanese general population?. J Intern Med 2003, 253:169-180.
3. Okamura T., Hayakawa T., Kadowaki T., et al. A combination of serum low albumin and above-average cholesterol level was associated with excess mortality. J Clin Epidemiol 2004, 57:1188-1195.
4. Nakamura Y., Okamura T., Tamaki S., et al. Egg consumption, serum cholesterol, and cause-specific and all-cause mortality: the National Integrated Project for Prospective Observation of Non-communicable Disease and Its Trends in the Aged, 1980 (NIPPON DATA80). Am J Clin Nutr 2004, 80:58-63.
5. Nakamura H., Arakawa K., Itakura H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 368:1155-1163.
6. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
7. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992, 33:1569-1582.
8. Bilheimer D.W., Grundy S.M., Brown M.S., Goldstein J.L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A 1983, 80:4124-4128.
9. Guidelines for Prevention of Atherosclerotic Diseases 2007, Japan Atherosclerosis Society, eds., Japan Atherosclerosis Society, Tokyo, Japan.
10. Mabuchi H., Inazu A., Higashikata T., et al. Present status of medications for hyperlipidemia-Kanazawa Lipid Assessment Survey (K-LAS). Progres Med 2000, 20:1629-1639.
11. Yamada N. New anti-hyperlipidemia drug- Ezetimibe. Med Sci Digest 2005, 31:331-332.
12. Garcia-Calvo M., Lisnock J., Bull H.G., et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005, 102:8132-8137.
13. Hawes B.E., O'Neill K.A., Yao X., et al. In vivo responsiveness to ezetimibe correlates with Niemann-Pick C1 Like-1 (NPC1L1) binding affinity: comparison of multiple species NPC1L1 orthologs. Mol Pharmacol 2007, 71:19-29.
14. Matsushima A. Clinical state and differential diagnosis-primary hypercholesterolemia. Watch/Think About Cholesterol 1999, 77-80. N. Nankodo Co, Tokyo, Japan. Y. Saito, N. Yamada (Eds.).
15. Lipitor [package insert] 2008, Pfizer, Inc, New York, NY.
16. Dose-related reduction of serum lipid levels in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Progress Med 1998, 18:1690-1723. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group.
17. Ballantyne C.M., Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Circulation 2003, 107:2409-2415.
18. Saito Y., Goto Y., Dane A., et al. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2003, 10:329-336.
19. Matsuzawa Y., Kita T., Mabuchi H., et al. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 2003, 67:287-294.
20. Sudhop T., Lütjohann D., Kodal A., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106:1943-1948.
21. Davidson M.H., Ballatyne C.M., Kerzner B., et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2,382 patients with primary hypercholesterolemia. Int J Clin Pract 2004, 58:746-755.
22. Pearson T.A., Denke M.A., McBride P.E., et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-On to Statin For Effectiveness (EASE) trial. Mayo Clin Proc 2005, 80:587-595.
23. Sakuma I., Kishimoto N., Nozaki Y., et al. Comparison of changes in various serum lipid parameters among treatment with atorvastatin 10 mg alone, 20 mg alone, and coadministration of atorvastatin 10 mg and ezetimibe 10 mg in identical patients with ischemic heart disease. Progress Med 2009, 29:1051-1057.
24. O'Keefe J.H., Cordain L., Harris W.H., et al. Optimal low-density lipoprotein is 50 to 70 mg/dl. J Am Coll Cardiol 2004, 43:2142-2146.
25. Kastelein J.J.P., Akdim F., Stroes E.S.G., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Eng J Med 2008, 358:1431-1443.
26. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet 2011, 377:2181-2192.
27. Califf R.M., Lokhnygina Y., Cannon C.P., et al. An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J 2010, 159:705-709.
28. Schectman G., Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med 1996, 125:990-1000.
29. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med 1999, 341:498-511.
30. Miettinen T.A., Gylling H., Lindbohm N., et al. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 2003, 141:131-137.
31. Crestor tablet [package insert] 2008, AstraZeneca, London, United Kingdom.